| abstract |
The present invention provides a process for preparing novel intermediates of Formula wherein, R 1 can be hydrogen, C 1 -C 4 alkyl, halogen, nitro, hydroxy, or C 1 -C 4 alkoxy; R x can be selected from hydrophobic residue of HMG-CoA reductase inhibitors; which can be effectively used for the preparation of HMG-CoA reductase inhibitors such as rosuvastatin and pharmaceutically acceptable salts thereof. |